ABIVAX Société Anonyme (AAVXF PINK) stock market data APIs
$85.6031
0(0%)
as of September 16, 2025
Try our APIs with
free plan!
ABIVAX Société Anonyme Financial Data Overview
Price chart is built with
Anychart
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod that is in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis, as well as in Phase 2b clinical trial to treat patients with Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.
Prev. Close
85.6031
Open
85.6031
High
85.6031
Low
85.6031
52 wk Range
5.81-88.9
Market Cap
6 507 M
Shares Outstanding
75 574 K
Revenue
6 023 K
EPS
-0.8657
Beta
0.127
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with ABIVAX Société Anonyme (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get ABIVAX Société Anonyme data using free add-ons & libraries
Get ABIVAX Société Anonyme Fundamental Data
ABIVAX Société Anonyme Fundamental data includes:
- Net Revenue: 6 023 K
- EBITDA: -185 652 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-09-08
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
ABIVAX Société Anonyme News
New
Abivax’s 580% surge hands biotech hedge funds a rare 2025 win
[Scientist taking a sample out of a petri dish using a pipette] DNY59/E+ via Getty Images Hedge funds specializing in biotech finally caught a break this summer, courtesy of a little-watched French d...
Abivax launches $400M U.S. public offering of ADSs
* Abivax SA (OTCPK:AAVXF [https://seekingalpha.com/symbol/AAVXF]) announced a ~$400M underwritten public offering of its American Depositary Shares in the U.S. * Each ADS represents one ordinary ...
Abivax Announces Launch of Public Offering
Abivax Abivax Announces Launch of Public Offering PARIS, France, July 23, 2025 – 10:15 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clin...
Abivax Hits The Stratosphere, Up 500%, On 'Potentially Disruptive' Results
Shares of Abivax hit the stratosphere Wednesday after the firm unveiled "potentially disruptive" results for its ulcerative colitis drug. Continue Reading View Comments
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
